「Altimmune」小白必看：Altimmune公司财报解

Altimmune基本情况

Company Overview

Altimmune (ALT) is a clinical-stage biopharmaceutical company focused on developing treatments for liver diseases and obesity. The company leverages its proprietary technology platform to create novel therapies that address significant unmet medical needs.

Shareholder Structure

Institutional investors hold approximately 60% of Altimmune's shares. Top institutional shareholders include Vanguard Group, BlackRock, and State Street Corporation. Insider ownership is around 10%, with the remaining 30% held by retail investors.

Operational Capability

Altimmune's revenue for the last fiscal year was $5 million, primarily from collaborations and grants. The company reported a net loss of $50 million, reflecting its focus on R&D. Cash reserves stand at $150 million, providing a runway for the next two years.

Competitive Edge

Altimmune's lead product, pemvidutide, is a GLP-1/glucagon dual receptor agonist targeting obesity. The company's proprietary technology platform offers a competitive advantage in developing next-generation therapies. Altimmune's pipeline also includes treatments for NASH and hepatitis B.

Growth Prospects

The global obesity drug market is projected to reach $50 billion by 2030. Altimmune's pemvidutide, currently in Phase 2 trials, could capture a significant market share if approved. The company is also exploring partnerships to expand its reach and accelerate development.

Significant Events

Recent milestones include positive Phase 1b data for pemvidutide and a strategic collaboration with a leading pharmaceutical company to advance its hepatitis B program. Altimmune also secured $100 million in funding through a public offering to support ongoing trials.

Company Overview Summary

Altimmune (ALT) is a promising biopharmaceutical company with a strong focus on liver diseases and obesity. Its proprietary technology platform and robust pipeline position it well in a growing market. With substantial cash reserves and strategic partnerships, Altimmune is poised for significant growth, making it an attractive investment opportunity.